Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Conditions
Advanced Hodgkin Lymphoma · Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope, Irvine, California, United States
Contact: Principal Investigator (Azra Borogovac, MD)Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
Contact: Principal Investigator (Joseph Schroers-Martin, MD)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Reid Merryman, MD)Washington University in St. Louis, St Louis, Missouri, United States
Contact: Principal Investigator (David Russler-Germain, MD)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Alison Moskowitz, MD)Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Ryan Lynch, MD)
Study leads
Ryan Lynch, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium